Suven Life Sciences Ltd Presenting Pre-Clinical Data of Their NCEs at Society For Neuroscience Annual Meeting (SFN-2010) At San Diego, USA

Published: Nov 12, 2010

HYDERABAD, INDIA (Nov 12, 2010) – Suven Life Sciences is presenting several data presentations from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2010 from 13th to 19 th of Nov held at San Diego, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro Scientists from all over the world covering all the major Pharma, biotech and research institutes will be participating.

Suven’s data presentations (9) covers the early-stage compounds from Nicotinic acetylcholine alpha-4-beta-2 receptor agonist and antagonist, Histamine-3 receptor antagonist, Serotonin 5-HT4 receptor agonist in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain. These data presentation highlights Suven’s continued commitment to exploring new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.

During SFN-2010 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global pharma majors for licensing and development of their clinical candidate SUVN-502.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration and Obesity through CNS targets.

For more information on Suven please visit our Web site at

Risk Statement: Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Back to news